<DOC>
	<DOCNO>NCT01423175</DOCNO>
	<brief_summary>ClAraC ( consist one dose clofarabine ara-C five day ) FLAMSA ( consist one dose fudarabine , amsacrine ara-C four day ) administer follow reduced-intensity condition regimen ( RIC ) set allogeneic stem cell transplantation ( SCT ) . The aim study explore antileukemic , immunosuppressive effect toxicity safety clofarabine combination ara-C set RIC allogeneic transplantation compare FLAMSA-protocol patient high-risk acute myeloid leukemia ( AML ) advance myelodysplastic syndrome ( MDS ) .</brief_summary>
	<brief_title>ClAraC FLAMSA Followed Stem Cell Transplantation Treat High Risk AML Advanced MDS</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>1 . Signed write informed consent 2 . Age &gt; 18 day inclusion 3 . Patients high risk AML advance MDS ( IPSS score ≥ intermediate 2 ) schedule allogeneic SCT HLAmatched relate unrelated donor 4 . Patients fulfil least one follow risk factor : Contraindication conventional conditioning therapy Relapsed refractory induction therapy 5 . Adequate renal , hepatic cardiac function indicate follow value : Serum creatinine ≤ 1.0 mg/dL ; serum creatinine &gt; 1.0 mg/dL , estimate glomerular filtration rate ( GFR ) must &gt; 60 mL/min/1.73 m2 Serum bilirubin ≤ 1.5 x upper limit normal ( ULN ) Aspartate transaminase ( AST ) / alanine transaminase ALT ) ≤ 2.5 x ULN Alkaline phosphatase ≤ 2.5 x ULN Left ventricular ejection fraction ≥ 50 % 6 . Capable understanding investigational nature , potential risk benefit study , able provide valid inform consent 7 . Female patient childbearing potential must negative serum pregnancy test day inclusion 8 . Female patient must meet one follow criterion : For female patient ≥ 50 year age day inclusion : Menopause since least 1 year Female patient &lt; 50 year age day inclusion meet follow criterion : menopause since least 1 year serum FSH level &gt; 40 MIU/mL serum estrogen level &lt; 30 pg/mL negative estrogen test 6 week surgical sterilization bilateral tubal ligation bilateral ovariectomy without hysterectomy Correct use two reliable contraception method time screen study minimum 90 day last administration study medication . This include every combination hormonal contraceptive ( oral , injection , transdermal patch , implant , cervical ring ) intrauterine device ( IUD ) barrier method ( diaphragm , cervical cap , Lea contraceptive , femidom condom ) spermicide . In case patient take hormone preparation suppression menstruation period aplasia , suitable effective method contraception discuss investigator use patient General sexual abstinence time screening , study minimum 90 day last administration study medication Having female sexual partner Monogamous relationship sterile male partner 9 . Male patient must meet one follow criterion : 6 week surgical sterilization vasectomy Correct use two reliable contraception method time screen study minimum 90 day last administration study medication . This include every combination hormonal contraceptive ( oral , injection , transdermal patch , implant , cervical ring ) intrauterine device ( IUD ) barrier method ( diaphragm , cervical cap , Lea contraceptive , femidom condom ) spermicide . General sexual abstinence time screening , study minimum 90 day last administration study medication Having male sexual partner Monogamous relationship sterile female partner 1 . Patients acute promyelocytic leukemia ( 15 ; 17 ) 2 . Current concomitant chemotherapy , radiation therapy , immunotherapy specify protocol 3 . Any anticancer therapy within 2 week study entry exception hydroxyurea . The patient must recover acute toxicity previous therapy 4 . Current participation clinical trial and/or participation another clinical trial within 30 day trial begin 5 . Have severe concurrent disease , history serious organ dysfunction disease involve heart ( heart insufficiency ≥ NYHA II ) , kidney ( serum creatinine &gt; 1.5 x normal serum level ) , liver ( bilirubin &gt; 1.5 x normal serum level , AST / ALT , AP &gt; 2.5 x normal serum level ) , organ system may place patient undue risk undergo treatment 6 . Patients systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) 7 . Human immunodeficiency virus ( HIV ) positivity 8 . Pregnant lactate patient 9 . Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result 10 . Have diagnosis another malignancy , unless patient diseasefree least 3 year follow completion curative intent therapy , follow exception : Patients treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia , regardless diseasefree duration , eligible study definitive treatment condition complete Patients organconfined prostate cancer evidence recurrent progressive disease base prostatespecific antigen ( PSA ) value also eligible study hormonal therapy initiate radical prostatectomy perform</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>high risk acute myeloid leukemia</keyword>
	<keyword>advanced myelodysplastic syndrome</keyword>
	<keyword>allogenic stem cell transplantation</keyword>
	<keyword>clofarabine</keyword>
</DOC>